5. There is a need for improved data methodology, accuracy and sharing across the sector. In the short term, accurate baseline data creation should be included in the RTPM planning process. In the longer term, a model to capture, maintain and share data from multiple sources should be developed, including protocols that outline how the data should be stored, used and shared; and that address practitioner and patient confidentiality and consent.
6. In the short term, naloxone education material should be incorporated into the Needle and Syringe Program (NSP). In the longer term, naloxone policy, procedures and training requirements should be embedded into permit requirements. A comprehensive GP, pharmacist and community education program that extends beyond the injecting drug use population should also be developed.
7. An essential and important step in improving access to pharmacotherapy services must be to provide adequate, publicly-funded remuneration to pharmacies by modifying the PBS listing of methadone and buprenorphine/naloxone. The listing should account for the chronic nature of opioid dependence as well as the cost and complex nature of providing the service. The Statewide Network is keen to collaborate with other stakeholders to advocate for these changes at state and federal level as opportunities arise.